ALNY
Price
$246.27
Change
-$2.89 (-1.16%)
Updated
Jan 17 closing price
Capitalization
31.76B
19 days until earnings call
GLYC
Price
$0.26
Change
+$0.01 (+4.00%)
Updated
Jan 17 closing price
Capitalization
16.78M
40 days until earnings call
Ad is loading...

ALNY vs GLYC

Header iconALNY vs GLYC Comparison
Open Charts ALNY vs GLYCBanner chart's image
Alnylam Pharmaceuticals
Price$246.27
Change-$2.89 (-1.16%)
Volume$558.13K
Capitalization31.76B
GlycoMimetics
Price$0.26
Change+$0.01 (+4.00%)
Volume$225.7K
Capitalization16.78M
ALNY vs GLYC Comparison Chart
Loading...
ALNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GLYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALNY vs. GLYC commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALNY is a Hold and GLYC is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (ALNY: $246.27 vs. GLYC: $0.26)
Brand notoriety: ALNY and GLYC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALNY: 80% vs. GLYC: 24%
Market capitalization -- ALNY: $31.76B vs. GLYC: $16.78M
ALNY [@Biotechnology] is valued at $31.76B. GLYC’s [@Biotechnology] market capitalization is $16.78M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALNY’s FA Score shows that 1 FA rating(s) are green whileGLYC’s FA Score has 0 green FA rating(s).

  • ALNY’s FA Score: 1 green, 4 red.
  • GLYC’s FA Score: 0 green, 5 red.
According to our system of comparison, ALNY is a better buy in the long-term than GLYC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALNY’s TA Score shows that 4 TA indicator(s) are bullish while GLYC’s TA Score has 4 bullish TA indicator(s).

  • ALNY’s TA Score: 4 bullish, 5 bearish.
  • GLYC’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, GLYC is a better buy in the short-term than ALNY.

Price Growth

ALNY (@Biotechnology) experienced а +3.48% price change this week, while GLYC (@Biotechnology) price change was -1.89% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.65%, and the average quarterly price growth was -1.89%.

Reported Earning Dates

ALNY is expected to report earnings on May 01, 2025.

GLYC is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALNY($31.8B) has a higher market cap than GLYC($16.8M). ALNY YTD gains are higher at: 4.658 vs. GLYC (4.418). GLYC has higher annual earnings (EBITDA): -36.73M vs. ALNY (-85.69M). ALNY has more cash in the bank: 2.78B vs. GLYC (14.4M). GLYC has less debt than ALNY: GLYC (262K) vs ALNY (1.3B). ALNY has higher revenues than GLYC: ALNY (2.1B) vs GLYC (10K).
ALNYGLYCALNY / GLYC
Capitalization31.8B16.8M189,286%
EBITDA-85.69M-36.73M233%
Gain YTD4.6584.418105%
P/E RatioN/AN/A-
Revenue2.1B10K20,950,000%
Total Cash2.78B14.4M19,306%
Total Debt1.3B262K496,947%
FUNDAMENTALS RATINGS
ALNY vs GLYC: Fundamental Ratings
ALNY
GLYC
OUTLOOK RATING
1..100
1424
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
87
Overvalued
PROFIT vs RISK RATING
1..100
23100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
5247
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GLYC's Valuation (87) in the Biotechnology industry is in the same range as ALNY (99). This means that GLYC’s stock grew similarly to ALNY’s over the last 12 months.

ALNY's Profit vs Risk Rating (23) in the Biotechnology industry is significantly better than the same rating for GLYC (100). This means that ALNY’s stock grew significantly faster than GLYC’s over the last 12 months.

GLYC's SMR Rating (99) in the Biotechnology industry is in the same range as ALNY (100). This means that GLYC’s stock grew similarly to ALNY’s over the last 12 months.

GLYC's Price Growth Rating (47) in the Biotechnology industry is in the same range as ALNY (52). This means that GLYC’s stock grew similarly to ALNY’s over the last 12 months.

GLYC's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ALNY (100). This means that GLYC’s stock grew similarly to ALNY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALNYGLYC
RSI
ODDS (%)
Bearish Trend 5 days ago
84%
Bullish Trend 5 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 5 days ago
77%
Bearish Trend 5 days ago
88%
Momentum
ODDS (%)
Bullish Trend 5 days ago
69%
Bullish Trend 5 days ago
81%
MACD
ODDS (%)
Bullish Trend 5 days ago
70%
Bullish Trend 5 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 5 days ago
71%
Bearish Trend 5 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 5 days ago
68%
Bearish Trend 5 days ago
88%
Advances
ODDS (%)
Bullish Trend 11 days ago
75%
Bullish Trend 12 days ago
81%
Declines
ODDS (%)
Bearish Trend 17 days ago
68%
Bearish Trend 6 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
77%
Bearish Trend 5 days ago
80%
Aroon
ODDS (%)
Bearish Trend 5 days ago
67%
Bearish Trend 5 days ago
87%
View a ticker or compare two or three
Ad is loading...
ALNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GLYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X104462.0400004705.133000
+4.72%
Bitcoin cryptocurrency
TSLA426.5012.68
+3.06%
Tesla
SPY597.585.94
+1.00%
SPDR® S&P 500® ETF Trust
AAPL229.981.72
+0.75%
Apple
GME27.51-0.21
-0.76%
GameStop Corp

ALNY and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALNY has been loosely correlated with IONS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ALNY jumps, then IONS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALNY
1D Price
Change %
ALNY100%
-1.16%
IONS - ALNY
50%
Loosely correlated
-2.63%
ARGX - ALNY
32%
Poorly correlated
-2.92%
DNA - ALNY
30%
Poorly correlated
+6.18%
GLYC - ALNY
30%
Poorly correlated
+3.09%
ABOS - ALNY
30%
Poorly correlated
+2.48%
More

GLYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLYC has been closely correlated with LYRA. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if GLYC jumps, then LYRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLYC
1D Price
Change %
GLYC100%
+3.09%
LYRA - GLYC
75%
Closely correlated
+1.87%
ROQAF - GLYC
72%
Closely correlated
N/A
EYPT - GLYC
47%
Loosely correlated
+2.89%
IONS - GLYC
35%
Loosely correlated
-2.63%
ALLO - GLYC
33%
Loosely correlated
-1.09%
More